Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Selective CD47 targeting with a bispecific antibody.

Literature DB >> 33388996

Selective CD47 targeting with a bispecific antibody.

Walter Ferlin¹, Krzysztof Masternak², Limin Shang².

Abstract

Entities: Gene

Mesh：

Substances：

Year: 2021 PMID： 33388996 DOI： 10.1007/s00262-020-02812-4

Source DB: PubMed Journal: Cancer Immunol Immunother ISSN： 0340-7004 Impact factor: 6.968

× No keyword cloud information.

6 in total

1. Elimination of tumor by CD47/PD-L1 dual-targeting fusion protein that engages innate and adaptive immune responses.

Authors: Boning Liu; Huaizu Guo; Jin Xu; Ting Qin; Qingcheng Guo; Nana Gu; Dapeng Zhang; Weizhu Qian; Jianxin Dai; Sheng Hou; Hao Wang; Yajun Guo
Journal: MAbs Date: 2017-12-20 Impact factor: 5.857

2. Autoimmune polyendocrine syndrome induced by immune checkpoint inhibitors: a systematic review.

Authors: Zhe Zhao; Xinfeng Wang; Xiu-Qi Bao; Jingwen Ning; Meiyu Shang; Dan Zhang
Journal: Cancer Immunol Immunother Date: 2020-11-16 Impact factor: 6.968

3. Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia.

Authors: Vanessa Buatois; Zoë Johnson; Susana Salgado-Pires; Anne Papaioannou; Eric Hatterer; Xavier Chauchet; Françoise Richard; Leticia Barba; Bruno Daubeuf; Laura Cons; Lucile Broyer; Matilde D'Asaro; Thomas Matthes; Simon LeGallou; Thierry Fest; Karin Tarte; Robert K Clarke Hinojosa; Eulàlia Genescà Ferrer; José María Ribera; Aditi Dey; Katharine Bailey; Adele K Fielding; Linda Eissenberg; Julie Ritchey; Michael Rettig; John F DiPersio; Marie H Kosco-Vilbois; Krzysztof Masternak; Nicolas Fischer; Limin Shang; Walter G Ferlin
Journal: Mol Cancer Ther Date: 2018-05-09 Impact factor: 6.261

4. Exploiting light chains for the scalable generation and platform purification of native human bispecific IgG.

Authors: Nicolas Fischer; Greg Elson; Giovanni Magistrelli; Elie Dheilly; Nicolas Fouque; Amélie Laurendon; Franck Gueneau; Ulla Ravn; Jean-François Depoisier; Valery Moine; Sylvain Raimondi; Pauline Malinge; Laura Di Grazia; François Rousseau; Yves Poitevin; Sébastien Calloud; Pierre-Alexis Cayatte; Mathias Alcoz; Guillemette Pontini; Séverine Fagète; Lucile Broyer; Marie Corbier; Delphine Schrag; Gérard Didelot; Nicolas Bosson; Nessie Costes; Laura Cons; Vanessa Buatois; Zoe Johnson; Walter Ferlin; Krzysztof Masternak; Marie Kosco-Vilbois
Journal: Nat Commun Date: 2015-02-12 Impact factor: 14.919

5. CD20-selective inhibition of CD47-SIRPα "don't eat me" signaling with a bispecific antibody-derivative enhances the anticancer activity of daratumumab, alemtuzumab and obinutuzumab.

Authors: Peter E van Bommel; Yuan He; Ilona Schepel; Mark A J M Hendriks; Valerie R Wiersma; Robert J van Ginkel; Tom van Meerten; Emanuele Ammatuna; Gerwin Huls; Douwe F Samplonius; Wijnand Helfrich; Edwin Bremer
Journal: Oncoimmunology Date: 2017-10-31 Impact factor: 8.110

6. Selective Blockade of the Ubiquitous Checkpoint Receptor CD47 Is Enabled by Dual-Targeting Bispecific Antibodies.

Authors: Elie Dheilly; Valéry Moine; Lucile Broyer; Susana Salgado-Pires; Zoë Johnson; Anne Papaioannou; Laura Cons; Sébastien Calloud; Stefano Majocchi; Robert Nelson; François Rousseau; Walter Ferlin; Marie Kosco-Vilbois; Nicolas Fischer; Krzysztof Masternak
Journal: Mol Ther Date: 2017-02-01 Impact factor: 11.454

6 in total

3 in total